Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/pibrentasvir in Renally-Impaired Adults With Chronic HCV
NCT03069365Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 3 trial of glecaprevir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Mar 2017; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03069365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069365.